Skip to main content

Effects of Combined Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2, and Interleukin-12 based Immunotherapy against Intracranial Glioma in the Rat

Abstract

Cytokines play a major role in the regulation of the immune system. Granulocyte–macrophage colony-stimulating factor (GM-CSF) has been shown to be useful for immunotherapy against glioma because it can stimulate dendritic cells to present tumor antigen. Interleukin-2 (IL-2) is involved in T-cell expansion, and interleukin-12 (IL-12) drives the T-helper cell type I response. Previous studies have shown that each of these cytokines alone can induce the regression of tumor cells. In the present study we postulated that peripheral infusion of GM-CSF along with either IL-2 or IL-12 and irradiated tumor cells can lead to increased survival from 9L brain tumors. 9L gliosarcoma cells (106) were implanted in the brains of syngeneic Fischer 344 rats. Osmotic minipumps were utilized for subcutaneous, continuous delivery of GM-CSF, either alone or with IL-2 or IL-12. Irradiated 9L cells were injected subcutaneously at various time points during treatment. Delayed-type hypersensitivity (DTH) and immunohistological analysis were used to further characterize the anti-tumor response. Treatment with GM-CSF and irradiated tumor cells led to an increase in survival rate in rats with intracranial 9L tumors when compared to untreated animals. The addition of IL-2 or IL-12 to the GM-CSF/tumor cell therapy further increased the survival rate up to 90%. The anti-tumor response was associated with vigorous DTH against 9L cells and increased infiltration of CD4+ and CD8+ lymphocytes into the tumor. These results suggest that the combined infusion of GM-CSF and other cytokines may be effective adjuvants in treating brain tumors.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release Interleukin 1 and factors inhibiting Interleukin 2-mediated effects. J Immunol 132: 1837, 1984

    Google Scholar 

  2. 2.

    Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12: 370-374, 1991

    Google Scholar 

  3. 3.

    Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E: Production of Prostaglandin E and an Interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129: 2413, 1982

    Google Scholar 

  4. 4.

    Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ranshoff J: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-852, 1995

    Google Scholar 

  5. 5.

    Sankhla SK, Nadkarni JS, Bhagwati SN: Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neuro-Oncol 27: 133-140, 1995

    Google Scholar 

  6. 6.

    Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13: 399-415, 1995

    Google Scholar 

  7. 7.

    Dranoff G, Jaffee E, Lazenby A, Golumber P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci 90: 3539-3543, 1993

    Google Scholar 

  8. 8.

    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Coarroll K, Guarnieri F, Longo DL, Kwak LW: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T-cells and generate potent systemic antitumor immunity. J Immunol 156: 3858-3865, 1996

    Google Scholar 

  9. 9.

    Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151: 622-628, 1994

    Google Scholar 

  10. 10.

    Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens Jr. AH, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537-1546, 1997

    Google Scholar 

  11. 11.

    Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS: Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4(6): 345-352, 1997

    Google Scholar 

  12. 12.

    Tseng SH, Hwang LH, Lin SM: Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 20(5): 334-342, 1997

    Google Scholar 

  13. 13.

    Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8(9): 1065-1072, 1997

    Google Scholar 

  14. 14.

    Tseng SH, Hsieh CL, Lin SM, Hwang LH: Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. Cancer Gene Ther 6(4): 302-312, 1999

    Google Scholar 

  15. 15.

    Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO: Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther 11(10): 1429-1438, 2000

    Google Scholar 

  16. 16.

    Lefrance F, Cool V, Velu T, Brotchi J, De Witte O: Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 20(5): 1077-1085, 2002

    Google Scholar 

  17. 17.

    Lumniczky K, Desaknai S, Mangel L, Szende B, Hamada H, Hidvegi EJ, Safrany G: Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 9(1): 44-52, 2002

    Google Scholar 

  18. 18.

    Jaffee EM, Thomas MC, Huang AY, Jauda KM, Levitsky HI, Pardoll DM: Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother 19: 1-8, 1996

    Google Scholar 

  19. 19.

    Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S: Systemic T-cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89(1): 42-51, 1998

    Google Scholar 

  20. 20.

    Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G: Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9(6): 1-8, 2000

    Google Scholar 

  21. 21.

    Kikuchi T, Joki T, Akasaki Y, Abe T, Ohno T: Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Cancer Lett 135: 47-51, 1999

    Google Scholar 

  22. 22.

    Kikuchi T, Joki T, Saitoh S, Hata Y, Abe T, Kato N, Kobayashi A, Miyazaki T, Ohno T: Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 80: 425-430, 1999

    Google Scholar 

  23. 23.

    Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA: Tumor-targeted IL-2 amplifies T-cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 96: 8591-8596, 1999

    Google Scholar 

  24. 24.

    Wigginton JM, Park J-W, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/Pulse IL-2: induction of local T-cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166: 1156-1168, 2001

    Google Scholar 

  25. 25.

    Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 42: 850-857, 1998

    Google Scholar 

  26. 26.

    Wallenfriedman MA, Conrad JA, DelaBarre L, Graupman PC, Lee G, Garwood M, Gregerson DS, Jean WD, Hall WA, Low WC: Effects of continuous localized infusion of granulocyte/macrophage colony stimulating factor (GM-CSF) and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 90: 1064-1071, 1999

    Google Scholar 

  27. 27.

    Thomas L: Discussion of Cellular and Humoral Aspects of the Hypersensitive States. Hoeber-Harper, New York, 1959, pp 529-532

    Google Scholar 

  28. 28.

    Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H: Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 155(2): 557-573, 1982

    Google Scholar 

  29. 29.

    Hui K, Grosveld F, Festenstein H: Rejection of transplantable AKR leukaemia cells following MHC DNA mediated cell transformation. Nature 31(5988): 750-752, 1984

    Google Scholar 

  30. 30.

    Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bernnink JR, Mule JJ, Yewdell JW, Rosenburg SA: Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 147(4): 1453-1459, 1991

    Google Scholar 

  31. 31.

    Pardoll DM: CancerVaccines. Nat Med 4(5): 525-531, 1998

    Google Scholar 

  32. 32.

    Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998

    Google Scholar 

  33. 33.

    Borrello I, Pardoll D: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 13: 185-193, 2002

    Google Scholar 

  34. 34.

    Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM: Controlled release, biodegradable cytokine depots: a new approach to cancer vaccine design. Cancer Res 53: 5841-5844, 1993

    Google Scholar 

  35. 35.

    Thompson RC, Pardoll DM, Jaffee EM, Ewend MG, Thomas MC, Tyler BM, Brem H: Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother 19(6): 405-413, 1997

    Google Scholar 

  36. 36.

    Glick RP, Lichtor T, Mogharbel A, Taylor CA, Cohen EP: Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41: 898-907, 1997

    Google Scholar 

  37. 37.

    Siemann DW, Lord EM, Keng PC, Wheeler KT: Cell subpopulation dispersed from solid tumours and separated by centrifugal elutriation. Br J Cancer 44: 100-108, 1981

    Google Scholar 

  38. 38.

    Dutcher JP: Therapeutic strategies for cytokines. Curr Opin Oncol 7: 566-571, 1995

    Google Scholar 

  39. 39.

    Hsieh C-S, Macatonia SE, Tripp CE, Wolf SF, O'Gara A, Murphy KM: Development of Th-1 CD4 T-cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547, 1993

    Google Scholar 

  40. 40.

    Rodolfo M, Colombo MP: Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19: 114-120, 1999

    Google Scholar 

  41. 41.

    Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, Feuerstein GZ: Tumor necrosis factor-α expression in ischemic neurons. Stroke 25: 1481-1488, 1994

    Google Scholar 

  42. 42.

    Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 55: 1902-1910, 1995

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jean, W.C., Spellman, S.R., Wallenfriedman, M.A. et al. Effects of Combined Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2, and Interleukin-12 based Immunotherapy against Intracranial Glioma in the Rat. J Neurooncol 66, 39–49 (2004). https://doi.org/10.1023/B:NEON.0000013477.94568.0f

Download citation

  • dendritic cells
  • glioma
  • granulocyte–macrophage colony-stimulating factor
  • immunotherapy
  • interleukin-2
  • interleukin-12